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Abstract
Background: The molecular mechanisms involved in the development and progression of clear cell renal cell
carcinomas (ccRCCs) are poorly understood. The objective of this study was to analyze the expression of dual-
specificity phosphatase 9 (DUSP-9) and determine its clinical significance in human ccRCCs.
Methods: The expression of DUSP-9 mRNA was determined in 46 paired samples of ccRCCs and adjacent normal
tissues by using real-time qPCR. The expression of the DUSP-9 was determined in 211 samples of ccRCCs and 107
paired samples of adjacent normal tissues by immunohistochemical analysis. Statistical analysis was performed to
define the relationship between the expression of DUSP-9 and the clinical features of ccRCC.
Results: The mRNA level of DUSP-9, which was determined by real-time RT-PCR, was found to be significantly
lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). An immunohistochemical analysis
of 107 paired tissue specimens showed that the DUSP-9 expression was lower in tumorous tissues than in the
adjacent non-tumorous tissues (p < 0.001). Moreover, there was a significant correlation between the DUSP-9
expression in ccRCCs and gender (p = 0.031), tumor size (p = 0.001), pathologic stage (p = 0.001), Fuhrman grade
(p = 0.002), T stage (p = 0.001), N classification (p = 0.012), metastasis (p = 0.005), and recurrence (p < 0.001).
Patients with lower DUSP-9 expression had shorter overall survival time than those with higher DUSP-9 expression
(p < 0.001). Multivariate analysis indicated that low expression of the DUSP-9 was an independent predictor for
poor survival of ccRCC patients.
Conclusion: To our knowledge, this is the first study that determines the relationship between DUSP-9 expression
and prognosis in ccRCC. We found that decreased expression of DUSP-9 is associated with poor prognosis in
ccRCC. DUSP-9 may represent a novel and useful prognostic marker for ccRCC.
Background
Clear cell renal cell carcinoma is a common urological
malignancy worldwide [1]. Although there have been
immense improvements in the treatment of ccRCC dur-
ing recent years, there is a gradual increase in the inci-
dence of this disease. ccRCC initially presents as
metastasis in 30% of patients, and up to 40% patients
undergoing nephrectomy develop local recurrence or
metastatic disease [2]. Although some environmental
and genetic factors have been found to be associated
with ccRCC, the molecular mechanisms involved in the
initiation and progression of ccRCC are still unclear [3].
Dual-specificity phosphatase 9 (DUSP-9) is a member
of the dual-specificity protein phosphatase subfamily
[4,5]. DUSP-9 negatively regulates members of the mito-
gen-activated protein (MAP) kinase superfamily (e.g.,
ERK, JNK, p38), which are associated with cellular pro-
liferation and differentiation [6,7]. Massively parallel
sequencing studies have revealed the down-regulation of
DUSP-9 in ccRCC [8]. However, since there is no pub-
lished report on this phenomenon, the relationship
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between the expression of DUSP-9 and clinical signifi-
cance needs to be clarified. In this study, we aimed to
explore the expression of DUSP-9 and its clinical signifi-
cance in ccRCC.
Methods
Patients and tissue specimens
Written informed consent was obtained from all
patients, and the study was approved by the institutional
review board of Sun Yat-sen University. For real-time
RT-PCR analysis, we collected 46 paired samples of
ccRCCs and adjacent normal tissues from patients who
underwent radical nephrectomy between February 2008
and December 2009. The 46 patients included 40 men
and 6 women with a median age of 50 years (range, 37-
75 years). The fresh tissues were immediately immersed
in RNAlater (Qiagen; Germany) after surgical resection,
stored at 4°C overnight to allow thorough penetration of
the tissue, and then frozen at -80°C. In addition, we per-
formed an immunohistochemical assay of 211 paraffin-
embedded samples of ccRCCs and 107 adjacent normal
renal tissue samples collected from patients between
1999 through 2007. The characteristics of these 211
patients are listed in Table 1. None of the patients
underwent radiotherapy or chemotherapy before sur-
gery. The histological and clinical diagnosis of the
tumors in all these patients was performed by the Can-
cer Center of Sun Yat-sen University. The disease stage
of each patient was classified or reclassified according to
the 2002 American Joint Committee on Cancer (AJCC)
staging system [9].
Real-Time qPCR
Total RNA was extracted using the TRIzol solution
(Invitrogen; Carlsbad, CA) according to the manufac-
turer’s protocol; RNase-free DNase I was used to
remove the DNA contamination. M-MLV reverse tran-
scriptase (Fermentas; American) was used according to
the manufacturer’s recommendations to treat 2 μg of
the total RNA for synthesizing the ?rst-strand cDNA.
The cDNA was then subjected to real-time quantitative
PCR for evaluation of the relative mRNA levels of
DUSP-9 and GAPDH (as an internal control) with
the corresponding primer pairs ( DUSP-9 sense
strand: 5’-TATGCCACGCCCTTTGAG-3’, DUSP-9
antisense strand: 5’-CACAGCAGGATGTAGGA-
GATGA-3’; GAPDH sense strand: 5’-GCTCTCTG
CTCCTCCTGTTC-3’, GAPDH antisense strand: 5’-
GACTCCGACCTTCACCTTCC-3’). Gene-speci?c
ampli?cation was performed using an Applied Biosystems
(ABI 7000) real-time PCR machine with a 20-μl PCR reac-
tion mixture containing 1 μl of cDNA (synthesized as
described above), 10-μl SYBR Green master mix (Invitro-
gen; Carlsbad, CA), and 40 nM of each pair of
oligonucleotide primers. The ampli?cation conditions were
50°C (2 min) and 95°C (2 min) for 1 cycle and 95°C (15
sec), 55°C (30 sec), and 72°C (40 sec) for 40 cycles. Regres-
sion curves were calculated for each sample, and the rela-
tive amount of mRNA was calculated from the threshold
cycles by using the software provided with the instrument
(Version 17.0 SPSS Inc.). Relative expression levels of the
target genes were normalized to the geometric mean of
the internal control gene, GAPDH. The data was analyzed
using the comparative threshold cycle (2-ΔCT) method.
Immunohistochemical assay
An immunohistochemical assay was performed to exam-
ine DUSP-9 expression in the 211 ccRCC samples and
Table 1 Correlation between DUSP-9 expression and
clinical pathologic features of the patients with clear cell
renal cell carcinoma




All cases 211 117 94 4.667 0.031
Male 140 85 55
Female 71 32 39
Age (yrs) 0.417 0.518
> 50 104 60 44
≤ 50 107 57 50
Pathologic stage 17.112 0.001
I 128 58 70
II 23 13 10
III 31 22 9
IV 29 24 5
Fuhrman Grade 14.492 0.002
I 39 28 11
II 123 72 51
III 34 10 24
IV 15 7 8
Tumor size (cm) 10.906 0.001
≤7 136 64 72
>7 75 53 22
T stage 14.914 0.001
T1 135 63 72
T2 35 21 14
T3, T4 41 33 8
N stage 6.248 0.012
N0 184 96 88
N+ 27 21 6
Metastasis 7.708 0.005
No 188 98 90
Yes 23 19 4
Recurrence 24.050 <0.001
No 181 88 93
Yes 30 29 1
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107 paired samples of adjacent normal renal tissue. All
procedures were performed using classical protocols. In
brief, paraffin-embedded specimens were cut into 5-μm
sections and baked at 65°C for 30 min. The sections
were deparaffinized with xylene and rehydrated, sub-
merged into 0.01 M citrate buffer (pH 6.0) antigen
retrieval buffer, and then microwaved for antigen retrie-
val. They were then treated with 3% hydrogen peroxide
in methanol to quench the endogenous peroxidase activ-
ity, which was followed by incubation with 10% bovine
serum albumin to block nonspecific binding. The
DUSP-9 protein was detected by using a mouse mono-
clonal antibody against DUSP-9 (Abcam; Cambridge,
MA, USA). The specimens were incubated overnight at
4°C with anti-DUSP-9 antibody (1:250). The negative
control for immunohistochemical analysis was obtained
by replacing the primary antibodies with an antibody
diluent. After being washed in phosphate buffered saline
(PBS), the sections were treated with MaxVision™
HRP-Polymer anti-Mouse IHC Kit (Maixin Bio; Fujian,
China) at 37°C for 15-20 min. The tissue sections were
immersed in 3-amino-9-ethyl carbazole, counterstained
with Mayer’s hematoxylin, dehydrated, and finally
mounted in Crystal Mount.
The formalin-fixed, paraffin-embedded sections were
reviewed for the degree of immunostaining and scored
by 2 independent observers. The proportion of cells
expressing DUSP-9 varied from 0% to 100%, and the
intensity of staining varied from weak to strong. The
proportion of DUSP-9- expressing tumor cells was
scored as follows: 0, no positive cells; 1, <5%; 2, 6%-25%;
3, 26%-50%; 4, 51%-75%; and 5, >75% according to Tsu-
chiya et al. The staining intensity was graded according
to the mean optical density [10-12]: 0, no staining; 1,
weak staining (light yellow); 2, moderate staining (yellow
brown); and 3, strong staining (brown). Staining index
was calculated as the multiplication of staining intensity
score and the proportion of DUSP-9-positive tumor
cells. We evaluated DUSP-9 expression in benign kidney
tissue and malignant lesions on the basis of the staining
index values, with scores of 0, 1, 2, 3, 4, 5, 6, 8, 9, 10,
12, and 15. The cutoff values for DUSP-9 expression
were chosen on the basis of a measure of heterogeneity
in overall survival rates, which was calculated using the
log-rank test. An optimal cutoff value was identified: a
staining index score of ≥5 was considered as high
DUSP-9 expression, whereas a staining index score of
≤4 was considered as low DUSP-9 expression.
Statistical analysis
All statistical analysis was carried out with the SPSS 17.0
statistical software package. In the real-time RT-PCR
and immunohistochemical assays, paired-sample t tests
were used to analyze the significance of the differences
in mRNA and protein expression between ccRCCs and
the adjacent normal tissues. The c2-test for proportion
was used to analyze the relationship between DUSP-9
expression and clinical significance. Survival curves were
plotted by the Kaplan-Meier method and compared by
the log-rank test. We determined that the assumption of
proportional hazards was met in all Cox regression
models. The significance of various variables for survival
was analyzed by the Cox proportional hazards model in
multivariate analysis. p < 0.05 was considered to be sta-
tistically significant.
Results
Real-time quantitative RT-PCR analysis of DUSP-9
expression
The transcription level of DUSP-9 was determined by
quantitative RT-PCR assays of 46 ccRCC tumor samples
and the paired adjacent normal tissue samples. In 45
tumor samples, the mRNA level of DUSP-9 was signifi-
cantly lower than that in the adjacent normal tissue
sample (p < 0.001, paired-sample t tests, Figure 1).
Immunohistochemical analysis of the expression of DUSP-
9 protein in 107 paraffin-embedded ccRCC samples (T)
and the paired adjacent normal renal tissue (N)
Expression and subcellular localization of protein were
determined by immunohistochemical analysis in 107
paraffin-embedded ccRCC tissues and 107 paired speci-
mens of adjacent normal tissues (Figure 2). In normal
renal tissue, specific DUSP-9 was localized mainly in the
cytoplasm of renal cells in the form of yellow-brown
granules (Figure 3A). The DUSP-9 protein expression in
the 102 tumor tissue samples was lower than that in the
adjacent normal tissue samples (p < 0.001, paired-sam-
ple t test, Figure 3B).
Immunohistochemical analysis of DUSP-9 expression in
211 ccRCC samples (T) and its relationship with the
clinical features
To further investigate the effect and the prognostic
value of DUSP-9, immunohistochemical analysis was
performed to assess the expression of DUSP-9 in 211
ccRCC tissue blocks. Overall, 117 of the 211 tumor
samples showed low expression of DUSP-9(score ≤4),
whereas 94 samples showed high expression (score ≥5).
The correlation between the expression of DUSP-9 and
various clinicopathological parameters are listed in
Table 1. Intense expression of DUSP-9 in ccRCC sam-
ples was correlated with gender (p = 0.031), pathologic
stage (p = 0.001), Fuhrman grade (p = 0.002), tumor
size (p = 0.001), T stage (p = 0.001), N classification (p
= 0.012), metastasis (p = 0.005), and recurrence (p <
0.001), but it was not correlated with age. Low expres-
sion of DUSP-9 was noted in 46.7%, 60.0%, and 80.5%
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Figure 1 Real-time quantitative RT-PCR analysis of DUSP-9 expression. The relative expression of DUSP-9 mRNA in RCC tumor tissue
samples was lower than that in the paired adjacent normal (N) tissue samples (n = 46, P < 0.001). The bottom and the top of the box represent
the 25th and the 75th percentile, respectively, and the band near the middle of the box is the 50th percentile (the median). The ends of the
whiskers represent the 2.5th percentile and the 97.5th percentile.
Figure 2 Decreased protein expression of DUSP-9 in ccRCC. The relative protein expression of DUSP-9 in ccRCC tumor (T) tissue samples
was lower than that in the paired adjacent normal (N) tissue samples (n = 107, P < 0.001). The bottom and top of the box are the lower and
upper quartiles, and the band near the middle of the box is the median. The ends of the whiskers represent the 2.5th percentile and the 97.5th
percentile. Four black spots represent the special value outliers.
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of T1, T2, and T3/4 stage ccRCCs respectively (p =
0.001, c2 test). Low expression of DUSP-9 was not
observed in 47.1% and 70.7% of ccRCCs with size ≤7 cm
and >7 cm respectively (p = 0.001, c2 test). Low expres-
sion of DUSP-9 was seen in 52.2% and 77.8% of N0 and
N1/2 stage ccRCCs respectively (p = 0.012, c2 test).
Low expression of DUSP-9 was seen in 52.1% and 82.6%
of ccRCCs with or without metastasis respectively (p =
0.005, c2 test). Low expression of DUSP-9 protein was
seen in 48.6% and 96.6% of ccRCCs with or without
recurrence respectively (p < 0.001, c2 test).
Survival analysis
Kaplan-Meier analysis and the log-rank test were used
to calculate the effect of the DUSP-9 expression on sur-
vival. The 5-year survival in the group of patients with
high DUSP-9 expression was 97%, but it was 62.1% in
the group of patients with low DUSP-9 expression (Fig-
ure 4A). The log-rank test showed that survival rates
were significantly different between these 2 groups (p <
0.001). Furthermore, the relationship of DUSP-9 expres-
sion with prognosis was determined in 211 patients,
which were divided into 3 subgroups depending on the
pathologic stage. Patients with tumors exhibiting high
DUSP-9 expression had significantly longer overall sur-
vival than those with low expression of DUSP-9 either
in the stage I plus II subgroup (n = 151; log-rank, p =
0.023; Figure 4B), the stage III sub group (n = 31; log-
rank, p = 0.036; Figure 4C), or the stage IV subgroup (n
= 29; log-rank, p = 0.038; Figure 4D). Patients with
tumors high DUSP-9 expression had significantly longer
overall survival than those with low expression of
DUSP-9 either in the Fuhrman grade I subgroup(n = 39;
log-rank, p = 0.005; Additional file 1 Figure S1A), II
subgroup (n = 123; log-rank, p < 0.0001; Additional file
1 Figure S1B), the stage III sub group (n = 34; log-rank,
p < 0.001; Additional file 1 Figure S1C), or the stage IV
subgroup (n = 15; log-rank, p = 0.019; Additional file 1
Figure S1D).
Univariate Cox regression analysis showed that tumor
size, T stage, N stage, metastasis, Fuhrman grade and
DUSP-9 expression were significantly associated with
overall survival (Table 2). Furthermore, multivariate Cox





Figure 3 Immunohistochemical analysis of the expression of DUSP-9 protein. DUSP-9 is mainly localized within the nuclei and cytoplasmic.
Immunostaining of the adjacent normal tissue samples(A) and the ccRCC tumor tissue samples(B) showed a sharp contrast between the
negatively stained infiltrative tumorous area.(B): Negative or weak DUSP-9 staining in cancerous tissue (400×). (C): Moderate DUSP-9 staining in
cancerous tissue(400×). (D): Strong DUSP-9 staining in most of tumor cells (400×).
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expression and Fuhrman grade were independent pre-
dictors for the overall survival of ccRCC patients (p =
0.005, respectively; Table 2), whereas the others factors
were not independently related to the survival of ccRCC
patients.
Discussion
Clear cell renal cell carcinoma accounts for about 2% of
all cases of cancers, with an annual increase of 1.5-5.9%
worldwide [13,14]. The initial treatment is usually a
radical or partial nephrectomy, which remains the main-
stay of curative treatment [15]. Unfortunately, ccRCC is
resistant to radiation therapy and chemotherapy, but
some tumors respond to molecular-targeted therapy.
Therefore, identification of specific molecular biomar-
kers of ccRCC is an essential prerequisite. Although the
numerous molecular markers, such as p53, vascular
endothelial growth factor (VEGF), hypoxia inducible fac-
tor, Ki67 (proliferation), have been investigated as prog-
nostic variables in ccRCC, the molecular mechanisms of
the initiation and progression of ccRCC still remain
unclear [16,17]. Massively parallel sequencing analysis
showed that DUSP-9 is downregulated in ccRCC [9].
DUSP-9 is a member of the dual-specificity protein
phosphatase subfamily and is expressed only in the pla-





Figure 4 Survival analysis of primary ccRCC patients (n = 211). (A) Overall survival. Kaplan-Meier survival analysis of primary ccRCC patients
(n = 211) after surgical resection with low DUSP-9 expression (n = 117) and high DUSP-9 expression (n = 94). The survival rate for patients in
the DUSP-9 low group was significantly lower than that for patients in the DUSP-9 positive group (log-rank test, p<0.001). (B) Pathological stage
I-II; (C) Pathological stage III; (D) Pathological stage IV. Statistical analysis of the difference between DUSP-9 high-expressing and low-expressing
tumors was compared in the I-II( B), III(C) and IV (D) patient subgroups. The longest follow-up time is 124 months.
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DUSP-9 is known to be associated with squamous cell
carcinoma (SCC) and can independently induce SCC
[5]. DUSP-9 inactivates the target kinases of squamous
carcinoma cells by dephosphorylating both the phospho-
serine/threonine and phosphotyrosine residues. DUSP-9
negatively regulates members of the mitogen-activated
protein (MAP) kinase superfamily (MAPK, p38, SAPK),
which are associated with cellular proliferation and dif-
ferentiation [18-20]. Molly Kulesz-Martin et al. found
that DUSP-9 reconstitution resulted in G2-M-associated
cell death and microtubule disruption. Loss of DUSP-9
was associated with SCC, and it independently induced
SCCs relative to benign tumors in mouse skin. Reconsti-
tution of DUSP-9 expression in malignant tumor cells
induces cell death and tumor suppression [6,21,22].
However, to our knowledge, the key feature of this
study is that this is the first study to report the clinical
significance of DUSP-9 in ccRCC. This is also the first
study aimed at evaluating the possibility of using DUSP-
9 as a clinically potential indicator for disease progres-
sion, as well as a prognostic marker for patient survival
in tumors.
In this study, we showed that DUSP-9 mRNA and
protein expression were significantly different between
the ccRCC and the adjacent normal renal tissue sam-
ples. Furthermore, immunohistochemical analysis
showed that DUSP-9 expression was moderate to low in
ccRCCs, while it was high in the adjacent normal tis-
sues. Accordingly, we found that DUSP-9 expression
was reduced in a large number of human clinical ccRCC
samples. The decreased expression of DUSP-9 was cor-
related with gender, pathologic stage, Fuhrman grade,
tumor size, recurrence, TNM stage, and prognosis.
Patients with lower DUSP-9 expression had shorter sur-
vival time, and those with higher DUSP-9 expression
had a longer survival time. In addition, the relationship
of DUSP-9 expression with prognosis was determined in
the patients, which were divided into 3 subgroups
depending on the pathologic stage. We found that
DUSP-9 could be a valuable prognostic marker for
ccRCC patients at all disease stages. Consistent with
previous reports of other cancers, low-expression of
DUSP-9 indicated poor prognosis for patients with
ccRCC.
DUSP-9 expression is correlated with low Fuhrman
grade. This result did not match with the other correla-
tions. However, in the survival analysis, we found that
patients with tumors high DUSP-9 expression had signifi-
cantly longer overall survival than those with low expres-
sion of DUSP-9 either in the Fuhrman grade I subgroup,
II subgroup, the stage III sub group, or the stage IV sub-
group. We observed that there are more cases with low
Fuhrman grade. In addition, this was a single hospital-
based, retrospective study. In addition to this observation,
we have, in particular, found that DUSP-9 expression is
correlated with low Fuhrman grade.
The TNM stage of ccRCC and Fuhrman grade are
closely related to its prognosis [23-25]. In our study, the
results of univariate Cox regression analysis showed that
tumor size, T stage, N stage, metastasis, Fuhrman grade
and DUSP-9 expression were significantly associated
with overall survival. Furthermore, multivariate Cox
regression analysis revealed that only DUSP-9 expres-
sion and Fuhrman grade were independent predictors
for the overall survival of ccRCC patients. Thus, our
findings indicate that the DUSP-9 expression level has a
significant correlation with clinicopathological features
and is a potential prognostic marker for ccRCC.
Our study was a single hospital-based, retrospective
study. It should be pointed out that unmeasured differ-
ences may exist and may distort the study results. A multi-
center or community-based prospective study with more
extensive collection of potential confounders is required.
In addition, the correlation of DUSP-9 with the above-
mentioned molecular markers needs to be investigated
further. Apparently, more studies are required to explore
the relationship between the DUSP-9 gene and other
genes such as p38 that may be associated with ccRCC.
Conclusion
In summary, we demonstrated the down-regulation of
DUSP-9 in ccRCC and its correlation with poor
Table 2 Cox Regression analysis of the overall survival rates associated with different prognostic variables in patients
with ccRCC






Tumor size (3.339-15.178) <0.001 (0.088-3.118) 0.478
T stage (2.177-4.177 ) <0.001 (0.629-5.052) 0.276
N stage (1.389-4.379 ) = 0.002 (0.438-3.119) 0.755
Metastasis (2.705-11.837 ) <0.001 (0.100-6.355) 0.832
Fuhrman Grade (35.53-630.43) <0.001 (27.23-569.2) <0.001
DUSP-9 (0.004-0.229 ) 0.001 (0.088-3.118) 0.008
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prognosis by using a large number of clinical samples.
Our results indicate the role of DUSP-9 as a prognostic
factor and a potential tumor suppressor in primary
ccRCC. Measurement of DUSP-9 expression in primary
ccRCC can help stratify the patients for prognosis.
Furthermore, DUSP-9 may be a new potential therapeu-
tic target for ccRCC in the future.
Additional material
Additional file 1: Additional file 1, Figure S1. Survival analysis of
difference Fuhrman grade.
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